Boehringer Ingelheim, in collaboration with Emirates Thoracic Society (ETS) and social media influencer Ghaith Marwan, ...

Boehringer Ingelheim, a leading biopharmaceutical company, has teamed up with the Emirates Thoracic Society (ETS) and social ...

Children diagnosed with interstitial lung disease often survive into adulthood, when they are likely to need care for related impairments.

When you visit Dubai Miracle Garden next, you will encounter an 'impossible-to-ignore' installation with an important health ...

Lung ultrasound (LUS) may be an effective screening tool for interstitial lung disease in patients with asymptomatic rheumatoid arthritis.

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

Background: Data examining the role of pulmonary rehabilitation (PR) in interstitial lung disease (ILD) are limited. We tested the hypothesis that PR can improve functional status and dyspnea in a ...

Understanding resilience—the ability of injured lung tissue to heal and regenerate—may be key to advancing the treatment and ...

The two positive studies mean that Boehringer can now seek approval for nerandomilast with a broad label claim in pulmonary ...

The team’s findings are described in the Jan. 2025 edition of the American Journal of Physiology in a paper entitled Convergent and Divergent Immune Aberrations in COVID-19, post-COVID-19-Interstitial ...

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...